Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...
The complement cascade, a proteolytic network originally characterised for host defence, exerts multifaceted roles within the central nervous system. Under physiological conditions, complement ...
Complement comprises a group of plasma and membrane proteins that provide an effective bridging function for innate and adaptive humoral immunity. Understanding complement pathophysiology is ...
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported interim data from Part 1 of an ongoing phase 1/2 trial of ARO-C3 in healthy people as a potential therapy for complement mediated diseases. The ...
Complement 3 glomerulopathy (C3G) is a rare kidney disorder—in many cases, the exact cause is unknown. Possible C3G causes include genetic mutations, autoantibodies, and certain autoimmune conditions.
Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
Silencing hepatic C3 with GalNAc-targeted siRNA nearly eliminated plasma complement, preserved acetylcholine receptors, and ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA ...
WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE)-- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...
JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced ...
Hosted on MSN
6 types of treatment for complement 3 glomerulopathy
Complement 3 glomerulopathy (C3G) is a rare kidney disease that is also considered an autoimmune disorder. There is no single cure for C3G, but several treatments may slow disease progression, protect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results